First human test of experimental cancer drug halted early
NCT ID NCT06052852
Summary
This was an early-stage study testing a new drug called BDC-3042, both by itself and combined with an existing immunotherapy (cemiplimab), in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find safe doses and see if the treatment caused tumors to shrink. The trial was terminated after enrolling 17 participants and did not proceed to later phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
NEXT Oncology
Austin, Texas, 78758, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
Stanford Cancer Center
Palo Alto, California, 94304, United States
Conditions
Explore the condition pages connected to this study.